Engineering Extracellular Vesicles Enriched with Palmitoylated ACE2 as COVID-19 Therapy (Adv. Mater. 49/2021)
Advanced Materials
; 33(49):2170388, 2021.
Article
in English
| Wiley | ID: covidwho-1557818
ABSTRACT
COVID-19 Therapy In their work reported in article number 2103471, Long Zhang, Fangfang Zhou, and co-workers fuse the S-palmitoylation-dependent plasma membrane (PM) targeting sequence with angiotensin converting enzyme 2 (ACE2) and engineer extracellular vesicles (EVs) on their surface enriched with palmitoylated ACE2 (PM-ACE2-EVs). The PM-ACE2-EVs can bind to the SARS-CoV-2 S-RBD with high affinity and block its interaction with cell-surface ACE2, thereby preventing SARS-CoV-2 from entering the host cell. This study provides a novel EV-based candidate for prophylactic and therapeutic treatment against COVID-19.
Full text:
Available
Collection:
Databases of international organizations
Database:
Wiley
Language:
English
Journal:
Advanced Materials
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS